Tibble Courtney Aavang, Cavaiola Tricia Santos, Henry Robert R
b University of California at San DiegoSchool of Medicine, 9500 Gilman Dr, La Jolla,CA 92093, USA.
a Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive CA 92122, USA.
Expert Rev Endocrinol Metab. 2013 May;8(3):247-259. doi: 10.1586/eem.13.20.
With the rapidly rising incidence of Type 2 diabetes and an increasing variety of medications available for treatment, choosing the ideal regimen for patients can be challenging. Longer-acting glucagon-like peptide-1 (GLP-1) receptor agonists and devices have been recently developed and include once-weekly exenatide, dulaglutide, albiglutide, semaglutide and miniosmotic pump ITCA650. Some of the attractive qualities of the GLP-1 receptor agonist class include its association with weightloss and potential for cardiovascular benefits. The longer-acting forms have been shown in several studies to produce equal or greater reduction in A1c and weight compared with the standard twice-daily formulation of exenatide. They also result in lower reported incidence of nausea, in the setting of a less frequent injection schedule that would be desirable to many diabetic patients. There are emerging data to suggest patients treated with longer-acting GLP-1 receptor agonists have improved cardiac parameters, some of which are independent of weight and A1c reductions.
随着2型糖尿病发病率的迅速上升以及可供治疗的药物种类日益增多，为患者选择理想的治疗方案可能具有挑战性。长效胰高血糖素样肽-1（GLP-1）受体激动剂和装置最近已被开发出来，包括每周一次的艾塞那肽、度拉鲁肽、阿必鲁肽、司美格鲁肽和微渗透泵ITCA650。GLP-1受体激动剂类药物的一些吸引人的特性包括其与体重减轻的关联以及对心血管有益的潜力。多项研究表明，与标准的每日两次注射的艾塞那肽制剂相比，长效剂型在降低糖化血红蛋白（A1c）和体重方面产生的效果相同或更好。在注射频率较低的情况下，它们还导致恶心的报告发生率较低，这对许多糖尿病患者来说是理想的。有新的数据表明，使用长效GLP-1受体激动剂治疗的患者心脏参数有所改善，其中一些与体重和A1c降低无关。
